On the recordMay 18, 2016
The notice and cure requirement will generate numerous litigation traps for the unwary and ultimately dissuade many individuals from pursuing their legitimate claims.
Source
congress.govEditor's note · Context
Conyers warns that new requirements will hinder legitimate claims under the ADA.
Share
More from John Conyers
Oct 24, 2017
I demand a recorded vote. A recorded vote was ordered. The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, this 5- minute vote on passage of the bill will be followed by a 5-minute vote on the motion to suspend the rules and pass…
Oct 24, 2017
I demand a recorded vote. The Acting CHAIR. Pursuant to clause 6 of rule XVIII, further proceedings on the amendment offered by the gentleman from Michigan will be postponed. Announcement by the Acting Chair The Acting CHAIR. Pursuant to…
Oct 25, 2017
Although H.R. 469 has many flaws, I am particularly concerned that the bill's broad and ill-defined requirements would effectively delay and possibly deter civil enforcement agencies from providing general relief in discrimination cases…
Jul 26, 2017
We should of course remain vigilant about pay-for-delay schemes, whereby branded drug manufacturers pay generic manufacturers to delay the entry of a version of branded drugs as the patent on the branded drug expires.
Other voices in this conversation
